Scarica l'app Stockscreener
20.07
0.15%
0.03
Dopo l'orario di chiusura:
19.68
-0.39
-1.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$20.04
Aprire:
$20
Volume 24 ore:
1.07M
Relative Volume:
0.70
Capitalizzazione di mercato:
$12.09B
Reddito:
$2.89B
Utile/perdita netta:
$684.26M
Rapporto P/E:
19.07
EPS:
1.0524
Flusso di cassa netto:
$958.82M
1 W Prestazione:
+3.88%
1M Prestazione:
+1.57%
6M Prestazione:
-11.90%
1 anno Prestazione:
-30.07%
Intervallo 1D:
$19.73
$20.18
Intervallo di 1 settimana:
$19.35
$20.18
Portata 52W:
$17.23
$30.41
Genmab Adr Stock (GMAB) Company Profile
Confronta GMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
20.07 | 12.09B | 2.89B | 684.26M | 958.82M | 1.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-01 | Downgrade | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Downgrade | Citigroup | Neutral → Sell |
| 2023-12-06 | Aggiornamento | UBS | Neutral → Buy |
| 2023-11-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Aggiornamento | DNB Markets | Sell → Buy |
| 2023-10-18 | Iniziato | Exane BNP Paribas | Underperform |
| 2023-09-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Iniziato | BTIG Research | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-31 | Iniziato | UBS | Neutral |
| 2023-05-12 | Iniziato | Morgan Stanley | Underweight |
| 2022-12-20 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-14 | Iniziato | William Blair | Mkt Perform |
| 2022-11-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-05-02 | Iniziato | Cowen | Market Perform |
| 2022-03-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-12-01 | Iniziato | Berenberg | Sell |
| 2021-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-01-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Downgrade | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-06-25 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Iniziato | Credit Suisse | Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | Morgan Stanley | Overweight |
| 2019-08-12 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Genmab Adr Borsa (GMAB) Ultime notizie
GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Genmab ADR (NASDAQ: GMAB) Jumps 1.19% In Recent Session. Here’s Everything You Need To Know. - Stocksregister
Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts - GlobeNewswire Inc.
AGCO Corp (AGCO) Beta Value: Understanding the Market Risk - News Heater
Evercore Inc’s Mixed Bag: Down -29.24% in 6 Months, Down -20.22% in 30 Days - investchronicle.com
DLocal Limited (DLO) Shares Decline Despite Market Challenges - The News Heater
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Genmab ADR Inc. (GMAB) Price Performance: The Role of Supply and Demand - The InvestChronicle
Views of Wall Street’s Leading Experts on Genmab ADR - SETE News
What is Core & Main Inc (CNM) Stock Return on Shareholders’ Capital? - SETE News
There is no doubt that Kite Realty Group Trust (KRG) ticks all the boxes. - SETE News
Sea Ltd ADR (NYSE: SE) Jumps 4.64%, Turning Investors Away - Stocks Register
Does Genmab ADR (NASDAQ: GMAB) Still Look Hot This Week? - Stocks Register
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN
Are Investors Undervaluing Genmab (GMAB) Right Now? - Yahoo Finance
Genmab stock holds Buy rating on positive trial results - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls - Yahoo Finance
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - Yahoo Finance
RBC Capital upgrades Genmab stock amid strong pipeline prospects - Investing.com
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results - MarketWatch
Stocks Flashing Renewed Technical Strength: Ascendis Pharma ADR - Investor's Business Daily
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo News Canada
New Strong Buy Stocks for January 11th - Yahoo Finance
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Genmab's chief development officer sells shares in US - MedWatch
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
INCY vs. GMAB: Which Stock Is the Better Value Option? - Yahoo Finance
Should You Buy Genmab (GMAB) Ahead of Earnings? - Yahoo Finance
Inside Genmab's blockbuster IPO - IR Magazine
Pipeline of Proprietary Antibodies - flow – Deutsche Bank
Genmab Stock Price, Quotes and Forecasts | NASDAQ:GMAB - Benzinga
Emergent BioSolutions Sees Its Composite Rating Rise To 97 - Investor's Business Daily
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO - Benzinga
Genmab's offering and listing in the USA - Bech-Bruun
Genmab AS (GMAB) Stock Price, Trades & News - GuruFocus
Genmab (GMAB) - Zacks Investment Research
Genmab IPO: What You Need To Know - Benzinga
Genmab Adr Azioni (GMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.32%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):